CN107405386A - 使用利西拉来治疗儿科2型糖尿病患者 - Google Patents

使用利西拉来治疗儿科2型糖尿病患者 Download PDF

Info

Publication number
CN107405386A
CN107405386A CN201680016033.2A CN201680016033A CN107405386A CN 107405386 A CN107405386 A CN 107405386A CN 201680016033 A CN201680016033 A CN 201680016033A CN 107405386 A CN107405386 A CN 107405386A
Authority
CN
China
Prior art keywords
lixisenatide
pharmaceutically acceptable
treatment
patient
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201680016033.2A
Other languages
English (en)
Chinese (zh)
Inventor
K·博格曼
A·安瑟兰-梅里
C·简
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis Deutschland GmbH
Original Assignee
Sanofi Aventis Deutschland GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52354814&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN107405386(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Aventis Deutschland GmbH filed Critical Sanofi Aventis Deutschland GmbH
Publication of CN107405386A publication Critical patent/CN107405386A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
CN201680016033.2A 2015-01-16 2016-01-15 使用利西拉来治疗儿科2型糖尿病患者 Pending CN107405386A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15151488.2 2015-01-16
EP15151488 2015-01-16
PCT/EP2016/050804 WO2016113404A1 (en) 2015-01-16 2016-01-15 Treatment of pediatric type 2 diabetes mellitus patients with lixisenatide

Publications (1)

Publication Number Publication Date
CN107405386A true CN107405386A (zh) 2017-11-28

Family

ID=52354814

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680016033.2A Pending CN107405386A (zh) 2015-01-16 2016-01-15 使用利西拉来治疗儿科2型糖尿病患者

Country Status (21)

Country Link
US (4) US20160235818A1 (https=)
EP (1) EP3244912B1 (https=)
JP (1) JP7274258B2 (https=)
KR (1) KR102614574B1 (https=)
CN (1) CN107405386A (https=)
AR (1) AR103415A1 (https=)
AU (1) AU2016207964B2 (https=)
CL (1) CL2017001843A1 (https=)
CR (1) CR20170376A (https=)
EA (1) EA035423B1 (https=)
ES (1) ES2895513T3 (https=)
IL (1) IL253460B (https=)
MX (1) MX381944B (https=)
PH (1) PH12017501290A1 (https=)
PL (1) PL3244912T3 (https=)
PT (1) PT3244912T (https=)
SG (1) SG11201705755UA (https=)
TN (1) TN2017000292A1 (https=)
TW (1) TWI706779B (https=)
WO (1) WO2016113404A1 (https=)
ZA (1) ZA201704512B (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS59913B1 (sr) 2008-10-17 2020-03-31 Sanofi Aventis Deutschland Kombinacija insulina i glp-1-agonista
PT3345593T (pt) 2009-11-13 2023-11-27 Sanofi Aventis Deutschland Composição farmacêutica compreendendo despro36exendina- 4(1-39)-lys6-nh2 e metionina
EP3229828B1 (en) 2014-12-12 2023-04-05 Sanofi-Aventis Deutschland GmbH Insulin glargine/lixisenatide fixed ratio formulation
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療
DE102019129444A1 (de) * 2019-10-31 2021-05-06 Lts Lohmann Therapie-Systeme Ag Lagtime-Verkürzung/Eisspray
WO2022221172A1 (en) * 2021-04-11 2022-10-20 Khurana Vikas Systems, devices and methods for enacting cyclical positive and negative pressure
WO2024133412A1 (en) 2022-12-21 2024-06-27 Novo Nordisk A/S Methods and systems for estimating fbg value from cgm data

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2324853A1 (en) * 2009-11-13 2011-05-25 Sanofi-Aventis Deutschland GmbH Lixisenatide as add-on to metformin in the treatment of diabetes type 2
CN103717232A (zh) * 2011-05-13 2014-04-09 赛诺菲-安万特德国有限公司 2型糖尿病中作为基础胰岛素的附加疗法的利西拉来
CN103841988A (zh) * 2011-05-13 2014-06-04 赛诺菲-安万特德国有限公司 用于治疗2型糖尿病患者的利西拉来和二甲双胍
CN103917241A (zh) * 2011-08-29 2014-07-09 赛诺菲-安万特德国有限公司 用于2型糖尿病患者中的血糖控制的药物组合
CN104066441A (zh) * 2011-10-28 2014-09-24 赛诺菲-安万特德国有限公司 2型糖尿病的治疗方案

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1076066A1 (en) 1999-07-12 2001-02-14 Zealand Pharmaceuticals A/S Peptides for lowering blood glucose levels
AR075204A1 (es) * 2009-01-29 2011-03-16 Boehringer Ingelheim Int Inhibidores de dpp-4 y composiciones farmaceuticas que los comprenden, utiles para tratar enfermedades metabolicas en pacientes pediatricos, particularmente diabetes mellitus tipo 2
EP2435061A4 (en) * 2009-05-28 2013-03-27 Amylin Pharmaceuticals Inc DAMPING GLP-1 RECEPTOR AGONIST COMPOUNDS
US20130090285A1 (en) * 2011-06-27 2013-04-11 Phasebio Pharmaceuticals, Inc. Methods of treatment with glp-1 receptor agonists

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2324853A1 (en) * 2009-11-13 2011-05-25 Sanofi-Aventis Deutschland GmbH Lixisenatide as add-on to metformin in the treatment of diabetes type 2
CN103717232A (zh) * 2011-05-13 2014-04-09 赛诺菲-安万特德国有限公司 2型糖尿病中作为基础胰岛素的附加疗法的利西拉来
CN103841988A (zh) * 2011-05-13 2014-06-04 赛诺菲-安万特德国有限公司 用于治疗2型糖尿病患者的利西拉来和二甲双胍
CN103917241A (zh) * 2011-08-29 2014-07-09 赛诺菲-安万特德国有限公司 用于2型糖尿病患者中的血糖控制的药物组合
CN104066441A (zh) * 2011-10-28 2014-09-24 赛诺菲-安万特德国有限公司 2型糖尿病的治疗方案

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
R E RATNER，等: "Dose-dependent effects of the once-daily GLP-1 receptor agonist lixisenatide in patients with Type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled trial", 《DIABET MED.》 *
杨建卓，等: "《糖尿病的预防及康复》", 31 January 2008, 黑龙江科学技术出版社 *
滕春波，等: "《胰腺发育与胰腺干细胞》", 31 July 2009, 东北林业大学出版社 *

Also Published As

Publication number Publication date
AU2016207964A1 (en) 2017-08-31
PH12017501290A1 (en) 2018-02-05
TW201639551A (zh) 2016-11-16
JP2018503644A (ja) 2018-02-08
EP3244912A1 (en) 2017-11-22
AR103415A1 (es) 2017-05-10
EA035423B1 (ru) 2020-06-11
IL253460A0 (en) 2017-09-28
KR102614574B1 (ko) 2023-12-18
US20160235818A1 (en) 2016-08-18
ES2895513T3 (es) 2022-02-21
AU2016207964B2 (en) 2021-10-14
TN2017000292A1 (en) 2019-01-16
NZ734595A (en) 2022-03-25
US20210187075A1 (en) 2021-06-24
ZA201704512B (en) 2019-07-31
TWI706779B (zh) 2020-10-11
CL2017001843A1 (es) 2018-02-23
BR112017015099A2 (pt) 2018-04-17
PT3244912T (pt) 2021-10-27
PL3244912T3 (pl) 2021-12-20
EP3244912B1 (en) 2021-08-18
MX381944B (es) 2025-03-13
EA201791611A1 (ru) 2017-11-30
US20190365864A1 (en) 2019-12-05
US20240173384A1 (en) 2024-05-30
MX2017009294A (es) 2017-11-20
CA2973632A1 (en) 2016-07-21
WO2016113404A1 (en) 2016-07-21
JP7274258B2 (ja) 2023-05-16
IL253460B (en) 2022-06-01
CR20170376A (es) 2017-09-25
KR20170102550A (ko) 2017-09-11
SG11201705755UA (en) 2017-08-30

Similar Documents

Publication Publication Date Title
US12186374B2 (en) Insulin glargine/lixisenatide fixed ratio formulation
TWI706779B (zh) 小兒第２型糖尿病病患之治療
Madhu et al. RSSDI clinical practice recommendations for management of type 2 diabetes mellitus, 2015
Yaw Adu-Sarkodie Clinical management of diabetes mellitus in the older adult patient
CA2973632C (en) Treatment of pediatric type 2 diabetes mellitus patients with lixisenatide
BR112017015099B1 (pt) Uso de lixisenatida e/ou um sal farmaceuticamente aceitável da mesma para tratar pacientes pediátricos portadores de diabetes mellitus tipo 2
HK1239556B (en) Treatment of pediatric type 2 diabetes mellitus patients with lixisenatide
TW202500575A (zh) 具有或不具有體重相關合併症之過重或肥胖成人之治療
NZ734595B2 (en) Treatment of pediatric type 2 diabetes mellitus patients with lixisenatide
Shourov A Survey on Prescription Pattern of Diabetes Mellitus
Harris CLINICAL PROTOCOL APPROVAL FORM
Brown et al. Signposts and Pathways: Multidimensional Care for Patients with Type 2 Diabetes

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20171128